Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer.
4 Feb, 2022 | 08:38h | UTCOriginal Study: Randomized Trial: Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC